Skip to main content
    A

    AstraZeneca PLC (AZN)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $182.36
    -1.66 (-0.90%)

    Market Cap: $286.07B

    Last updated: Nov 17, 2026 at 4:43 PM ET

    AstraZeneca PLC (AZN) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    AstraZeneca (AZN) has a market cap of $286.07B and an enterprise value of $309.56B. Its trailing P/E of 22.2x is below its 10-year median of 39.7x.

    Total Valuation

    Enterprise value is 8.21% above the market cap, as debt exceeds cash.

    Market Cap$286.07B
    Enterprise Value$309.56B
    Latest price (Nov 17, 2026)$182.36

    Key Dates

    The last ex-dividend date was Aug 7, 2026.

    Last Earnings DateOct 30, 2026
    Last Ex-Dividend DateAug 7, 2026
    Last Payment DateSep 8, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count held steady in the quarter ended Sep 30, 2026 and held steady over 2 years.

    Shares Outstanding1.56B
    Shares Change (YoY)-0.06%
    Shares Change (QoQ)0.00%
    Share Count Growth (2Y CAGR)0.00%

    Valuation Ratios

    Sales and book value multiples are 4.6x and 5.5x. Its year-end P/E ranged from 25.2x to 64.0x from 2016 to 2025.

    P/E Ratio22.2x
    Forward P/E17.5x
    P/S Ratio4.6x
    Forward P/S4.5x
    P/B Ratio5.5x
    P/FCF Ratio30.5x
    P/OCF Ratio21.5x
    PEG Ratio1.8

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 14.4x EBITDA and 33.0x free cash flow.

    EV / Earnings28.2x
    EV / Sales5.0x
    EV / EBITDA14.4x
    EV / EBIT20.7x
    EV / FCF33.0x

    Price Statistics

    The stock is up 4.48% over 52 weeks and trades 7.47% above its 50-day average.

    Beta (1Y)0.22
    52-Week Change+4.48%
    1-Month Change+11.23%
    3-Month Change+10.55%
    6-Month Change-0.58%
    5-Year Change+49.61%
    10-Year Change+229.54%
    Total Return (1Y)+7.55%
    Total Return (3Y CAGR)+14.83%
    Total Return (5Y CAGR)+12.37%
    Return vs SPY (1Y)-7.61%
    Max Drawdown (1Y)-25.84%
    Max Drawdown (3Y)-27.87%
    Sharpe Ratio (1Y)0.14
    Correlation with SPY (1Y)0.11
    50-Day Average$169.68
    200-Day Average$179.34
    52-Week Range$152.40 to $209.11
    RSI (14 Days)57.7
    Average Volume (20 Days)2.89M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.01x current liabilities, and total debt is 0.61x shareholder equity.

    Current Ratio1.01x
    Quick Ratio0.79x
    Debt / Equity0.61x
    Debt / EBITDA1.47x
    Debt / FCF3.37x
    Interest Coverage8.45x

    Returns and Efficiency

    Return on invested capital is 14.95% over the last 12 months, against a 5-year average of 8.55%.

    Return on Equity (ROE)21.28%
    Return on Assets (ROA)9.18%
    Return on Invested Capital (ROIC)14.95%
    Return on Capital Employed (ROCE)16.91%
    ROE (5Y Average)12.54%
    ROA (5Y Average)5.03%
    ROIC (5Y Average)8.55%
    Asset Turnover0.53x
    Inventory Turnover1.79x
    Receivables Turnover3.85x
    Cash Conversion Cycle-386 days

    Taxes

    Income tax took 17.02% of pretax income over the last 12 months.

    Income Tax (TTM)$2.25B
    Effective Tax Rate17.02%

    Scores

    AZN has an Altman Z-Score of 3.61, in the safe zone above 2.99, and a Piotroski F-Score of 8 of 9, in the strong band of 8 or 9.

    Altman Z-Score3.61
    Altman Z ZoneSafe
    Piotroski F-Score8 of 9
    Piotroski StrengthStrong

    Income Statement

    Revenue was $62.17B over the last 12 months.

    Revenue$62.17B
    Gross Profit$49.79B
    Operating Income$14.71B
    Pretax Income$13.25B
    Net Income$10.99B
    EBITDA$21.37B
    EBIT$14.96B
    Reported EPS (TTM)$8.20

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 43.14% of the $119.71B in total assets.

    Cash and Equivalents$7.92B
    Total Debt$31.41B
    Net Debt$23.49B
    Working Capital$180.68M
    Shareholder Equity$51.64B
    Tangible Book Value-$7.56B
    Total Assets$119.71B
    Total Liabilities$67.99B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $4.01B of capital spending, operating cash flow left $9.32B of free cash flow.

    Operating Cash Flow$13.33B
    Capital Expenditures$4.01B
    Free Cash Flow$9.32B
    FCF Per Share$6.01
    Depreciation and Amortization$6.41B
    Dividends Paid$4.95B

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 23.66%, against a 5-year average of 14.21%.

    Gross Margin80.09%
    Operating Margin23.66%
    Pretax Margin21.31%
    Net Margin17.68%
    EBITDA Margin34.38%
    EBIT Margin24.07%
    FCF Margin14.99%
    Gross Margin (5Y Average)76.76%
    Operating Margin (5Y Average)14.21%
    Net Margin (5Y Average)10.24%

    Growth

    Revenue grew 9.82% a year over 3 years, and EPS 12.20% a year.

    Revenue Growth (3Y CAGR)+9.82%
    Revenue Growth (5Y CAGR)+17.15%
    EPS Growth (3Y CAGR)+12.20%
    EPS Growth (5Y CAGR)+17.80%
    FCF Growth (3Y CAGR)+6.21%
    FCF Growth (5Y CAGR)+31.64%
    Operating Income Growth (3Y CAGR)+54.08%

    Revenue and profit by year

    Dividends and Yields

    AZN pays out 12.51% of earnings as dividends.

    Dividend Per Share (Annual)$2.14
    Dividend Yield1.17%
    Dividend Growth (3Y CAGR)+3.29%
    Dividend Growth (5Y CAGR)+2.40%
    Payout Ratio12.51%
    FCF Payout Ratio53.10%
    Earnings Yield4.50%
    FCF Yield3.28%
    Shareholder Yield1.74%

    Full dividend history

    Stock Splits

    The last split was a 1-for-2 reverse split on Feb 2, 2026.

    Last Split DateFeb 2, 2026
    Split TypeReverse split
    Split Ratio1:2

    Peer Position

    Against 9 similar companies, AZN has the 5th highest P/E.

    P/E Ratio22.2x vs 19.8x median
    P/S Ratio4.6x vs 5.3x median
    ROIC14.95% vs 13.48% median
    Dividend Yield1.17% vs 2.69% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 7.15% and EPS growth at 29.04% a year over the next 5 fiscal years.

    Revenue Growth Forecast (5Y CAGR)+7.15%
    EPS Growth Forecast (5Y CAGR)+29.04%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About AZN

    What is AZN's market cap?

    AstraZeneca has a market cap of $286.07B. Its enterprise value, which adds debt and subtracts cash, is $309.56B.

    What is AZN's P/E ratio?

    AstraZeneca has a trailing P/E ratio of 22.2x and a forward P/E of 17.5x.

    How many shares of AZN are outstanding?

    AstraZeneca has 1.56B shares outstanding. The count is down 0.06% from a year earlier.

    Does AZN pay a dividend?

    Yes. AstraZeneca pays $2.14 a share a year, a dividend yield of 1.17%.

    How much debt does AZN have?

    AstraZeneca has $31.41B of total debt and $7.92B of cash and equivalents, a net debt position of $23.49B.